Biological and Thrombolytic Properties of Proenzyme and Active Forms of Human Urokinase – IV. Variability in Fibrinolytic Response of Plasma of Several Mammalian Species

Summary

The fibrinolytic and fibrinogenolytic properties of recombinant pro-urokinase (Rec-pro-UK) and recombinant urokinase (Rec- UK) were compared with those of natural urokinase (Nat-UK) and of tissue-type plasminogen activator (t-PA) in an in vitro system consisting of ¹²⁵I-labeled autologous plasma clots immersed in plasma of humans, five primate species, dogs, rabbits and pigs. With each of the four plasminogen activators, a dose-dependent clot lysis was observed, the degree of which differed, however, very markedly from one species to the other.

At a concentration of 100 IU/ml of urokinase extensive plasma clot lysis was obtained in plasma of man, Macaca mulatta, Macaca fascicularis and Macaca radiata, while the plasma clots of Papio cynocephalus, Papio anubis and rabbit, dog and pig were much more resistant to lysis. No significant differences in the extent of lysis were observed between Rec-pro-UK and Rec-UK nor between Rec-UK and Nat-UK. Comparable degrees of lysis were obtained with t-PA at 3- to 5-fold lower concentrations. Lysis with Rec-UK or Nat-UK was always associated with extensive activation of the fibrinolytic system in plasma, evidenced by fibrinogen breakdown and plasminogen activation and a2-antiplasmin consumption. With t-PA, extensive clot lysis was obtained in the absence of fibrinolytic activation in the plasma. With Rec-pro-UK the response was intermediate; at high concentrations (200 IU/ ml) extensive lysis in the reactive species was associated with fibrinogen consumption, while at intermediate concentrations (50-100 IU/ml) significant clot lysis was obtained in the reactive species in the absence of marked activation of the fibrinolytic system in the plasma.

Keywords

Pro-urokinase - Fibrinolysis - Species variability

• References

• 1 Zamarron C, Lijnen HR, Van HoefB, Collen D. Biological and thrombolytic properties of proenzyme and active forms of human urokinase. I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinase obtained from human urine or by recombinant DNA technology. Thromb Haemostas 1984; 52: 15-18
• 2 Collen D, De CockF, Lijnen HR. Biological and thrombolytic properties of proenzyme and active forms of human urokinase. II. Turnover of natural and recombinant urokinase in rabbits and squirrel monkeys. Thromb Haemostas 1984; 52: 19-23
• 3 Husain S, Gurewich V, Lipinski B. Purification and partial characterization of a single-chain high-molecular-weight form of urokinase from human urine. Arch Biochem Biophys 1983; 220: 31-38
• 4 Sumi H, Toki N, Sasaki K, Mihara H. Comparative properties of single and double polypeptide chains of high molecular weight urokinase. In Progress in Fibrinolysis. Davidson JF, Bachmann F, Bouvier CA, Kruithof EK O. (eds) Churchill Livingstone; Edinburgh: 1983. pp 165-167
• 5 Collen D, Stassen JM, Blaber M, Winkler M, Verstraete M. Biological and thrombolytic properties of proenzyme and active forms of human urokinase. III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis. Thromb Haemostas 1984; 52: 24-26
• 6 Matsuo O, Rijken DC, Collen D. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro. Thromb Haemostas 1981; 45: 225-229
• 7 Kominger C, Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemostas 1981; 46: 561-566
• 8 Heyneker HL, Holmes WE, Vehar GA. Preparation of functional human urokinase proteins. European Patent Application nr 83103629.8, Publication nr 0092182A2, European Patent Office. Munich, West-Germany: